EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> DBV Technologies priced a $150 million (€121 million) stock offering. The round precedes a planned submission for approval of a peanut allergy therapy in the U.S. Statement

> Motif Bio delayed a filing for approval of its antibiotic, iclaprim. The biotech now plans to submit an application to the FDA in the second quarter. Release

>  Bavarian Nordic entered into a collaboration with the U.S. Department of Defense to develop a vaccine against the equine encephalitis virus. The deal is worth up to $36 million (€29 million). Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Shield Therapeutics outlined the analyses it presented to the FDA at a pre-NDA meeting. The pivotal trial missed its hematology-focused primary endpoint, but Shield thinks the result was affected by confounding data. Shield is now waiting to learn the FDA’s take. Release

> Arix Bioscience raised £87 million ($123 million) from new and existing investors. The financing will enable Arix to add to the 13 investments it has made so far. Statement

> Deinove secured an option on Redx Pharma’s bacterial topoisomerase inhibitor program. The deal gives Deinove nine months to evaluate the program before deciding whether to pay a fee to exercise its option. Release

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.